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Abstract
KCNT2 variants resulting in substitutions affecting the Arg190 residue have been
shown to cause epileptic encephalopathy and a recognizable facial gestalt. We report
two additional individuals with intellectual disability, dysmorphic features, hyper-
trichosis, macrocephaly and the same de novo KCNT2 missense variants affecting the
Arg190 residue as previously described. Notably, neither patient has epilepsy.
Homology modeling of these missense variants revealed that they are likely to dis-
rupt the stabilization of a closed channel conformation of KCNT2 resulting in a con-
stitutively open state. This is the first report of pathogenic variants in KCNT2 causing
a developmental phenotype without epilepsy.
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1 | INTRODUCTION
Potassium (K+) channels are a large family of pore-forming membrane
proteins. They represent a heterogeneous group of voltage and
ligand-gated ion channels with wide-ranging effects on many
physiological processes including cell excitability (Jeevaratnam
et al., 2018), hormone secretion (Ashcroft & Rorsman, 2013), and apo-
ptosis (Szabò et al., 2010). In neurons, K+ channels are essential for
maintaining the inward-negative resting membrane potential. Their
opening, which occurs in response to a range of signals, leads to K+
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efflux from the cell, resulting in the membrane potential becoming
more negative and hence repolarization. The ability of K+ channels to
repolarize and hyperpolarize nerve and muscle cells helps to control
action potential frequency and duration (Humphries & Dart, 2015). K+
channels can be categorized by the stimulus to which they are acti-
vated and include voltage-gated (KV), calcium-activated (KCa), inwardly
rectifying (KIR), ATP-sensitive (KATP), and sodium-activated (KNa)
channels. A recent systematic review identified 19 potassium
channelopathies implicated in a variety of neurodevelopmental disor-
ders (Kessi et al., 2020).
Humans have two K(Na) channel subunits, Slack and Slick,
encoded by KCNT1 (OMIM 608167) and KCNT2 (OMIM 610044),
respectively, that rectify outwardly. KCNT1 and KCNT2 share 74%
sequence identity (Bhattacharjee et al., 2003), show similar single-
channel conductance, modulate the hyperpolarization that occurs fol-
lowing repetitive firing and form hetero-tetrameric channels in several
brain regions such as the oculomotor nucleus and the medial nucleus
of the trapezoid body (Chen, Kronengold, et al., 2009). A key differ-
ence between KCNT1 and KCNT2 is that KCNT1 channels have an
absolute requirement for Na+ for channel opening, whereas KCNT2
channels maintain a basal level of activity in the absence of Na+
(Bhattacharjee et al., 2003).
Pathogenic variants in KCNT1 have been recently identified to
cause autosomal dominant nocturnal frontal lobe epilepsy (OMIM
#615005) and epilepsy of infancy with migrating focal seizures (Barcia
et al., 2019), as well as, early infantile epileptic encephalopathy with
severe dystonia (OMIM #614959) (Gertler et al., 2019; Martin
et al., 2014). The majority of cases are caused by gain-of-function
variants, however, a single missense variant resulting in loss-of-
function (p.Phe932Ile) has been described in a patient with epilepsy
and leukoencephalopathy (Evely et al., 2017).
KCNT2 has recently been described as a human disorder gene
(OMIM #617771) with only eight patients in total reported so far.
Mao et al. reported two patients with epilepsy of infancy with
migrating focal seizures and de novo truncating variants in KCNT2
(p.Lys564* and p.Leu48Glufs*43) (Mao et al., 2020). Gururaj et al.
reported a patient with a de novo p.Phe240Leu missense variant
and epileptic encephalopathy with no dysmorphic features (Gururaj
et al., 2017). The p.Phe240 residue is situated in the channel pore
helix and the authors concluded that this particular variant causes a
“change-in-function” by altering a K+ channel that is usually
upregulated by Cl to become a Na+ channel down-regulated by
Cl. Inuzuka et al. (2020) reported another patient with a de novo
p.Thr242Asn variant, which lies in the same transmembrane
domain, with a non-dysmorphic epileptic encephalopathy phenotype
(Inuzuka et al., 2020). Alagoz et al. (2020) also reported two patients
with de novo missense variants (p.Asn182Ile and p.Leu880Met,
located in the S4 helical and C-terminal cytoplasmic domains,
respectively) in KCNT2 and epileptic encephalopathy without dys-
morphic features.
Ambrosino et al. described two individuals with de novo missense
variants in KCNT2, both affecting the arginine residue at position
190 (p.Arg190His and p.Arg190Pro) (Ambrosino et al., 2018).
The probands had epilepsy, intellectual disability, hypertrichosis, and
coarse facial features. Electrophysiological studies revealed a gain-of-
function and constitutive activation for both variants. The gain-of-
function effect was more pronounced with the substitution of
positively charged arginine with neutral proline than with histidine.
This suggested that substitution with partially protonated histidine
may allow for the maintenance of some, but not all, charge inter-
actions necessary for channel function. Prior to reports of pathogenic
variants in KCNT2 in humans, the mechanism of closure of the KCNT2
channel had been investigated by Dai et al. (2010) who performed
electrophysiological studies on cRNA-transduced Xenopus oocytes.
p.Arg190 was identified as an important candidate residue for channel
gating due to its location in a transmembrane linker region. Mutation
of p.Arg190 to Glu, Gln, and Ala showed that charge reversal
or neutralization led to constitutive activation of the channel
(Dai et al., 2010). Of note, substitution of p.Arg190 for another posi-
tively charged amino acid, lysine, resulted in channels with wild-type
properties (i.e., normal function).
Given so few cases are reported, the mutational spectrum, clinical
features, and the genotype–phenotype relations in KCNT2-related
disorders remain undefined. We report two new individuals with
a recognizable neurodevelopmental disorder without epilepsy and
recurrent de novo KCNT2 variants affecting the Arg190 residue. Using
homology modeling, we advance the inferences made by Ambrosino
et al. on models of the wild-type KCNT2 by showing that substitution
of p.Arg190 with uncharged amino acids results in a likely constitu-
tively open conformation.
2 | METHODS
2.1 | Case ascertainment
The index case was identified through a local re-analysis project of
genome data from the 100,000 Genomes project via a previously
described pipeline (Faundes et al., 2018; Vaz et al., 2019). A second
unreported case was identified through a search of the DECIPHER
database (DECIPHER 408952). Clinical features were compiled and
compared with previously reported cases. Informed consent was
obtained from the families of both individuals.
2.2 | Homology modeling
Human KCNT2 was modeled on chicken KCNT1 in open (PDB
5u70) and closed (PDB 5u76) conformations. Clustal Omega v1.2.3
(Sievers et al., 2011) was used to align the sequence of the chicken
KCNT1 template PDB files (PDB 5u70 and PDB 5u76) to the
human KCNT2 FASTA sequence. Homology models were subse-
quently generated using Modeler 9.24 (Eswar et al., 2006). Twenty
models were built in each case and the model with the lowest Dis-
crete Optimized Protein Energy score was chosen for visualization
and analysis in KiNG 2.23 (Chen, Davis, & Richardson, 2009).
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Mutant channels seen in patients (p.Arg190His and p.Arg190Pro), or
created by Dai et al (p.Arg190Ala, p.Arg190Glu, p.Arg190Gln, and p.
Arg190Lys) or present in the gnomAD database (Karczewski
et al., 2020) (p.Arg190Cys) were created by amending the FASTA
sequence for KCNT2 in the alignment file and running through
Modeller9.24 separately.
3 | RESULTS
3.1 | Case reports
3.1.1 | Individual 1
The proband is the second child born to non-consanguineous Cauca-
sian parents. Pregnancy was uncomplicated and she was born at term
by normal vaginal delivery weighing 3.3 kg (+0.15 SD). Concerns
regarding hypotonia and delay in her general development were
raised during early infancy. She sat unsupported at 1 year of age and
was walking unsteadily at the age of 2 years. She started using single
words at the age of 2 years and three-word phrases at the age of
4 years 2 months. She attended school with a statement of educa-
tional needs due to severe learning difficulties. Currently, at the age
of 32 years, she lives in residential care. She has never suffered from
seizures.
She developed pubic and axillary hair at the age of 8 years before
menarche aged 14 years. Her periods were irregular and a pelvic ultra-
sound scan which revealed polycystic ovaries. She had impaired
fasting glucose at the age of 18 years and was treated with metformin
until 21 years, when her fasting glucose had normalized. At 14 years,
her height was 170 cm (+1.46 SD), her weight was 50.6 kg (+0.13
SD), and occipitofrontal circumference (OFC) was 58 cm (+3.35 SD).
At her last clinic review, aged 27 years, her OFC was 60.5 cm (+5.12
SD). She has mild synophrys, epicanthic folds, large palpebral fissures,
thick hair, long eyelashes, and diastema (Figure 1a). Her facial features
have coarsened with time.
A CT brain aged 2 years was reported as normal. Her urine muco-
polysaccharides, amino acids and organic acids profile, and plasma
very long chain fatty acids were all within normal limits. Her thyroid
function was also normal. Fragile X testing, karyotyping, and chromo-
somal microarray showed normal results.
The proband and her parents were recruited to the 100,000
Genomes Project (Caulfield et al., 2019) and analysis using Intellectual
disability (v1.066), Mucopolysaccharidosis (v1.2), and Undiagnosed
metabolic disorder (v1.397) panels did not reveal any pathogenic vari-
ants. Panel-agnostic re-analysis of the trio genome data (Faundes
et al., 2018) (Vaz et al., 2019) revealed a de novo KCNT2
NM_198503.3:c.569G > C (p.Arg190Pro) missense variant. The vari-
ant was classified as pathogenic according to the American College of
Medical Genetics (ACMG) guidelines (PS2, PM2, PM5, PP3, PP2)
(Richards et al., 2015). No other plausible candidates were identified
during this re-analysis.
3.1.2 | Individual 2
The proband was born to non-consanguineous Caucasian parents.
She has an older maternal half-sister and a younger brother. Preg-
nancy had been unremarkable except for an iron transfusion at
32 weeks for anemia. She was born at 41 weeks, weighing 4.88 kg
(+3.15 SD) with birth OFC 38 cm (+3.48 SD).
She first sat unsupported aged 6 months but delay in motor
development was noted at 17 months as she was falling frequently
and appeared to have poor leg coordination. She was walking inde-
pendently by age 22 months. Her speech and language development
was significantly delayed. Currently, aged 5 years 7 months, she
speaks a few single words but also uses non-verbal gestures. She has
moderate intellectual disability and with autistic traits. Her behavior
has been described as hyperactive with a tendency for aggressive out-
bursts and she has difficulties with sleep requiring melatonin. She has
never had seizures. She has slightly reduced tone in her legs but oth-
erwise normal neurological examination. She suffers with constipation
which has required regular Movicol and is also prone to wheezing epi-
sodes, for which she takes preventative inhalers.
At 4 years 8 months, her height was 108 cm (+0.57 SD) and OFC
54.4 cm (+3.00 SD). She has prominent eyebrows and long lashes, big
ears, small square teeth, widely spaced teeth and hypertrichosis,
mainly affecting her arms and back (Figure 1b). Her brain MRI scan at
18 months of age was reported to be normal. Gene-agnostic trio
exome sequencing in the clinical setting revealed a de novo
NM_198503.3:c.569G > A (p.Arg190His) missense variant. This vari-
ant was also classified as Pathogenic according to the American Col-
lege of Medical Genetics (ACMG) guidelines (PS2, PM2, PM5, PP3,
PP2) (Richards et al., 2015). No other likely causative rare de novo or
biallelic variants were identified through the exome sequencing
analysis.
3.2 | Homology modeling
KNa channels resemble Kv channels in topography with six hydropho-
bic, transmembrane segments (S1-S6) along with a pore-lining loop
found between S5 and S6 (Kaczmarek, 2013). Subunits assemble as
tetramers to form a functional channel. The KCNT2 p.Arg190 residue
is located within the S4 and S5 linker region and is evolutionary con-
served among species (Ambrosino et al., 2018). p.Arg190 creates a
constriction between the cytoplasmic domains immediately before
(S5) and after (S6) the pore-forming domain. This constriction likely
stabilizes the channel in closed state (Figure 1b). To understand the
mechanistic basis of the condition in the cases presented here, we
performed homology modeling. Modeling of the human wild-type
KCNT2 revealed a network of charge interactions that we postulate
to stabilize the channel in the closed state. These interactions occur
between p.Arg190 and three other charged residues: p.Lys366, p.
Asp369, and p.Arg372 (Figure 1c). These charge interactions are
predicted to be lost in the open conformation (Figure 1c).
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Modeling showed that the patient variants (p.Arg190His and p.
Arg190Pro) abrogate the charge interactions and the channel is
predicted to remain in a constitutively open conformation (Figure 1c).
The distances between residue 190 and the other charged residues
are increased in all mutated forms, including the p.Arg190Cys variant,
which is present in 1/125,050 heterozygotes in gnomAD and compa-
rable to the wild-type open conformation, with the exception of the
p.Arg190Lys variant (Supplementary Table 1). The only mutant to
retain wild-type electrophysiological properties, as reported by Dai
et al., is the p.Arg190Lys substitution. Modeling this variant shows
maintenance of the network of charge interactions with p.Lys366, p.
Asp36,9 and p.Arg372 (Figure 1c) and the distances between these
residues appear to be closer to the wild-type closed conformation.
4 | DISCUSSION
We describe two individuals with de novo missense KCNT2 variants
affecting the same residue at p.Arg190, which has been implicated in
epileptic encephalopathy previously. Individual #1 presented with
F IGURE 1 (a) Facial gestalt of cases
with de novo KCNT2 variants. Individual
#1 (left) and individual 2 (right). Note
prominent eyebrows, thick hair, and
diastema. (b) Schematic of KCNT2
(domains taken from Uniprot Q6UVM3).
(c) Model of KCNT2 in open and closed
state. Mutant models on the closed state
show a reversion to an open state
conformation
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hypotonia, developmental delay, severe intellectual disability, and
macrocephaly. Individual #2 presented with developmental delay,
moderate intellectual disability, and autistic traits. Both individuals
share hirsutism, prominent eyebrows, long eyelashes, and diastema,
all of which were also seen in the two previously reported p.Arg190
cases (Ambrosino et al., 2018). Their previous occurrence in affected
individuals and absence of these variants from population databases
lends weight to their pathogenicity.
Comparison of the clinical features of the two individuals
described here with the eight previously described cases showed that
all individuals were affected by intellectual disability. Epilepsy was
seen in all mutation types although our two p.Arg190 cases did not
have seizures, those reported by Ambrosino et al. did. Notably, intel-
lectual disability, neonatal hypotonia, hirsutism, thick hair, prominent
eyebrows, long eyelashes, and diastema were present in all cases with
variants affecting p.Arg190 (Table 1). Both our cases had
macrocephaly, which was not reported previously. Interestingly, the
individuals with truncating variants reported by Mao et al and
the individuals with other missense variants reported by Gururaj et al.,
Inuzuka et al., and Alagoz et al. all shared epilepsy and intellectual dis-
ability but no dysmorphic features nor macrocephaly (Table 1).
KCNT2-associated neurodevelopmental disorders appear to show a
genotype–phenotype correlation with missense variants affecting p.
Arg190 causing a syndromic disorder with a recognizable facial
gestalt. In these two cases, however, epilepsy was absent and we
describe a new association with macrocephaly.
The occurrence of macrocephaly in these two individuals is note-
worthy as constitutive activity of other ion channels, such as KCNB1,
leading to cytoplasmic K+ loss have been linked with excessive neu-
ronal apoptosis (Kondratskyi et al., 2015), although a decrease in cyto-
plasmic K+ is not obligatory for apoptosis (Börjesson et al., 2011).
Interestingly, KCNT2 expression, unlike that of KCNT1, has been
found to be predominantly under control of NF-κβ, which is released
during stressful stimuli such as hypoxia and injury (Tomasello
et al., 2015). As a putative neuroprotective channel, constitutive acti-
vation of KCNT2 may not have the same effect on neuronal apoptosis
as other previously studied ion channels.
The basis of the phenotypic differences between KCNT2 p.
Arg190 variants and other mutations is likely due to the effect of the
variants on the channel function. Patch-clamp experiments on
the missense variant (p.Pro240Leu) described by Gururaj et al.
showed a change in function, which was suggested to be the patho-
genic mechanism. The missense variants reported by Inuzuka et al. (p.
Thr242Asn) and Alagoz et al. (p.Asn182Ile and p.Leu880Met) were
not investigated for their effect on channel function. In the case of
the loss-of-function variants (p.Lys564* and p.Leu48Glufs*43)
reported by Mao et al., whole-cell patch-clamp experiments showed a
decrease in global current density in heteromeric mutant channels.
Given that KCNT2 appears to be tolerant of loss-of-function variants
(pLi 0.04, pLEOUF 0.37), haploinsufficiency would appear unlikely to
be the mechanism. mRNA or protein studies were not performed to
prove these variants were truly loss-of-function and indeed, cells co-
transfected with wild-type KCNT1, wild-type KCNT2 and also
KCNT2p.Leu48Glufs*43 showed currents similar to cells expressing
KCNT1 alone, which may indicate a dominant negative effect for this
variant.
Using homology modeling, we have shown that p.Arg190 partici-
pates in key interactions with neighboring charged residues in order
to stabilize the closed channel state. Substitution of the charged argi-
nine residue with uncharged amino acids results in a constitutive open
state and recapitulates the gain-of-function effects seen in previous
electrophysiological studies.
KCNT2 is highly expressed in the hippocampus and amygdala,
where KCNT1 is relatively less highly expressed (Human Protein Atlas
available from http://www.proteinatlas.org) (Pontén et al., 2008;
Uhlen et al., 2017). This difference in expression may suggest then
KCNT2 functions independently from KCNT1 in these regions
(Bhattacharjee et al., 2005). KCNT2 also has a consensus ATP binding
site (amino acids 1032–1038), which, when occupied by ATP, inhibits
activity of the channel. A unique attribute of KCNT2 is the require-
ment for ATP to dissociate from a site near the C-terminus, in the
presence of elevated intracellular Na+, to allow channel activation.
During times of metabolic stress, such as hypoxia or even epileptiform
activity, which both cause a reduction in ATP and elevation in intracel-
lular Na+, it is postulated that KCNT2 channels play a neuroprotective
role by limiting excitability and maintaining a hyperpolarized mem-
brane potential (Bhattacharjee et al., 2003). How a gain-of-function
variant could bring about the phenotype observed in our cases is not
currently understood. The occurrence of both loss-of-function and
gain-of-function variants in the spectrum of KCNT2-associated devel-
opmental disorders indicates a delicate balance in maintaining mem-
brane potential, which is disturbed in these conditions.
The occurrence of hypertrichosis in several K+ channelopathies is
also notable. The opening of intracellular K+ channels has been
suggested as a mechanism regulating hair growth. Several anti-
hypertensive compounds, most notably minoxidil and diazoxide, have
the known side effect of excessive hair growth (Suchonwanit
et al., 2019; Uno et al., 1990). These have been found to induce
hypertrichosis by enhancing the flux of potassium ions (Buhl
et al., 1992). It is interesting that in the cases described here, and by
Ambrosino et al., with gain-of-function variants, hypertrichosis is a
common finding, whereas this was not reported by Gururaj et al. nor
Mao et al. for those individuals with change-of-function or loss-of-
function variants. In mice, KCNT2 channels are expressed in the dor-
sal root ganglia, specifically in Calcitonin gene-related peptide
(CGRP)-containing neurons (Tomasello et al., 2017), which is interest-
ing, given that CGRP, along with other neuropeptides such as
substance P, is known to regulate hair growth (Samuelov et al., 2012).
In a similar manner, gain-of-function variants in ABCC9, which contrib-
utes a subunit to SUR2, a KATP channel, cause Cantu syndrome
(OMIM #239850). Cantu syndrome is another developmental disorder
sharing phenotypic overlap, particularly hypertrichosis, with the
KCNT2 p.Arg190Arg/His phenotype. SUR2 is also a known pharma-
cological target of minoxidil (Ohko et al., 2020).
Notably, the American College of Medical Genetics consensus
guidelines (Richards et al., 2015) on variant interpretation place the
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identification of a variant affecting the same amino acid residue as a
known pathogenic variant in the “moderate” category as evidence for
pathogenicity (PM5). It could be surmised that consideration should
be given to the precise amino acid substitution and the effect this
may have on macromolecular structure as we would strongly suspect
that other uncharged substitutions affecting p.Arg190 in KCNT2
would be pathogenic. Our homology modeling of p.Arg190Cys seen
in gnomAD would predict this to result in the same gain-of-function
seen with the other charge-neutralizing substitutions, however, the
distance between the charged residues is less affected than the other
variants. In this case, most distances are shorter than those seen in
the p.Arg190Ala substitution, which has the shortest distances for all
experimentally proven gain-of-function variants (Supplementary
Table 1). Of note, this variant does not occur in the gnomAD control
group but rather the “non-cancer” group and hence some variants at
this position may be either benign or have reduced penetrance.
In conclusion, we report two new cases of variants affecting the p.
Arg190 residue in KCNT2 causing a recognizable neurodevelopmental
disorder. In our cases, epilepsy was not a feature and we also expand
this phenotype to include macrocephaly. Differential diagnosis included
metabolic storage disorders. We show that p.Arg190 is a critical
charged residue and reversal or neutralization of this charge is
predicted to result in constitutive channel activation.
ACKNOWLEDGMENTS
We thank all family members for their participation and collaboration.
We would also like to thank Exeter Genomics Laboratory who under-
took the Whole Exome Sequencing for Individual 2. Dr Adam Jackson
is supported by Solve-RD. The Solve-RD project has received funding
from the European Union's Horizon 2020 research and innovation
program under grant agreement No 779257. This research was made
possible through access to the data and findings generated by the
100,000 Genomes Project. The 100,000 Genomes Project is managed
by Genomics England Limited (a wholly owned company of the
Department of Health and Social Care). The 100,000 Genomes Pro-
ject is funded by the National Institute for Health Research and NHS
England. The Wellcome Trust, Cancer Research UK and the Medical
Research Council have also funded research infrastructure. The
100,000 Genomes Project uses data provided by patients and col-
lected by the National Health Service as part of their care and
support.
CONFLICT OF INTERESTS
All authors have no conflicts of interest to declare for this work.
AUTHOR CONTRIBUTION
Adam Jackson wrote the manuscript and performed re-analysis of
genomic data for Individual #1. Homology modeling was completed
by Adam Jackson under the guidance of Simon Lovell. Jill Clayton-
Smith and Helen Stewart provided clinical details for both individuals.
HR provided genetic insights from a clinical diagnostic perspective
and analyzed the exome data for Individual #2. Genomics England



























































































































































































































































































































































































































































JACKSON ET AL. 7
Siddharth Banka, Jill Clayton-Smith and Simon Lovell supervised the
findings of this work. All authors discussed the results and contributed
to the final manuscript.
DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were gener-






Alagoz, M., Kherad, N., Bozkurt, S., & Yuksel, A. (2020). New mutations in
KCNT2 gene causing early infantile epileptic encephalopathy type 57:
Case study and literature review. Acta Biochimica Polonica, 67(3),
431–434. https://doi.org/10.18388/abp.2020_5364.
Ambrosino, P., Soldovieri, M. V., Bast, T., Turnpenny, P. D., Uhrig, S.,
Biskup, S., Döcker, M., Fleck, T., Mosca, I., Manocchio, L., Iraci, N.,
Taglialatela, M., & Lemke, J. R. (2018). De novo gain-of-function vari-
ants in KCNT2 as a novel cause of developmental and epileptic
encephalopathy. Annals of Neurology, 83, 1198–1204.
Ashcroft, F. M., & Rorsman, P. (2013). K(ATP) channels and islet hormone
secretion: New insights and controversies. Nature Reviews. Endocrinol-
ogy, 9, 660–669.
Barcia, G., Chemaly, N., Kuchenbuch, M., Eisermann, M., Gobin-
Limballe, S., Ciorna, V., Macaya, A., Lambert, L., Dubois, F.,
Doummar, D., Billette de Villemeur, T., Villeneuve, N., Barthez, M.-A.,
Nava, C., Boddaert, N., Kaminska, A., Bahi-Buisson, N., Milh, M.,
Auvin, S., … Nabbout, R. (2019). Epilepsy with migrating focal seizures:
KCNT1 mutation hotspots and phenotype variability. Neurology.
Genetics, 5, e363.
Bhattacharjee, A., Joiner, W. J., Wu, M., Yang, Y., Sigworth, F. J., &
Kaczmarek, L. K. (2003). Slick (Slo2.1), a rapidly-gating sodium-
activated potassium channel inhibited by ATP. Journal of Neuroscience,
23, 11681–11691.
Bhattacharjee, A., von Hehn, C. A. A., Mei, X., & Kaczmarek, L. K. (2005).
Localization of the Na+activated K+ channel Slick in the rat central
nervous system. The Journal of Comparative Neurology, 484, 80–92.
Börjesson, S. I., Englund, U. H., Asif, M. H., Willander, M., & Elinder, F.
(2011). Intracellular K+ concentration decrease is not obligatory for
apoptosis*. The Journal of Biological Chemistry, 286, 39823–39828.
Buhl, A. E., Waldon, D. J., Conrad, S. J., Mulholland, M. J., Shull, K. L.,
Kubicek, M. F., Johnson, G. A., Brunden, M. N., Stefanski, K. J.,
Stehle, R. G., Gadwood, R. C., Kamdar, B. V., Thomasco, L. M.,
Schostarez, H. J., Schwartz, T. M., & Diani, A. R. (1992). Potassium
channel conductance: A mechanism affecting hair growth both in vitro
and in vivo. The Journal of Investigative Dermatology, 98, 315–319.
Caulfield M, Davies J, Dennys M, Elbahy L, Fowler T, Hill S, Hubbard T,
Jostins L, Maltby N, Mahon-Pearson J, McVean G, Nevin-Ridley K,
Parker M, Parry V, Rendon A, Riley L, Turnbull C, Woods K. 2019. The
National Genomics Research and Healthcare Knowledgebase.
Chen, H., Kronengold, J., Yan, Y., Gazula, V.-R., Brown, M. R., Ma, L.,
Ferreira, G., Yang, Y., Bhattacharjee, A., Sigworth, F. J., Salkoff, L., &
Kaczmarek, L. K. (2009). The N-terminal domain of slack determines
the formation and trafficking of Slick/slack Heteromeric sodium-
activated potassium channels. The Journal of Neuroscience, 29, 5654–
5665.
Chen, V. B., Davis, I. W., & Richardson, D. C. (2009). KING (Kinemage, next
generation): A versatile interactive molecular and scientific visualiza-
tion program. Protein Science, 18, 2403–2409.
Dai, L., Garg, V., & Sanguinetti, M. C. (2010). Activation of Slo2.1 channels
by niflumic acid. The Journal of General Physiology, 135, 275–295.
Eswar, N., Webb, B., Marti-Renom, M. A., Madhusudhan, M. S.,
Eramian, D., Shen, M.-Y., Pieper, U., & Sali, A. (2006). Comparative
protein structure modeling using Modeller. Current Protocols in Bioin-
formatics, Chapter 5:Unit-5.6. https://doi.org/10.1002/0471250953.
bi0506s15.
Evely, K. M., Pryce, K. D., & Bhattacharjee, A. (2017). The Phe932Ile muta-
tion in KCNT1 channels associated with severe epilepsy, delayed mye-
lination and leukoencephalopathy produces a loss-of-function channel
phenotype. Neuroscience, 351, 65–70.
Faundes, V., Newman, W. G., Bernardini, L., Canham, N., Clayton-Smith, J.,
Dallapiccola, B., Davies, S. J., Demos, M. K., Goldman, A., Gill, H.,
Horton, R., Kerr, B., Kumar, D., Lehman, A., McKee, S., Morton, J.,
Parker, M. J., Rankin, J., Robertson, L., … Banka, S. (2018). Histone
lysine Methylases and demethylases in the landscape of human devel-
opmental disorders. American Journal of Human Genetics, 102,
175–187.
Gertler, T. S., Thompson, C. H., Vanoye, C. G., Millichap, J. J., &
George, A. L. (2019). Functional consequences of a KCNT1 variant
associated with status dystonicus and early-onset infantile encepha-
lopathy. Annals of Clinical Translational Neurology, 6, 1606–1615.
Gururaj, S., Palmer, E. E., Sheehan, G. D., Kandula, T., Macintosh, R.,
Ying, K., Morris, P., Tao, J., Dias, K.-R., Zhu, Y., Dinger, M. E.,
Cowley, M. J., Kirk, E. P., Roscioli, T., Sachdev, R., Duffey, M. E.,
Bye, A., & Bhattacharjee, A. (2017). A de novo mutation in the sodium-
activated potassium channel KCNT2 alters ion selectivity and causes
epileptic encephalopathy. Cell Reports, 21, 926–933.
Humphries, E. S. A., & Dart, C. (2015). Neuronal and cardiovascular potas-
sium channels as therapeutic drug targets. Journal of Biomolecular
Screening, 20, 1055–1073.
Inuzuka, L. M., Macedo-Souza, L. I., Della-Ripa, B., Monteiro, F. P.,
Ramos, L., Kitajima, J. P., Garzon, E., & Kok, F. (2020). Additional obser-
vation of a de novo pathogenic variant in KCNT2 leading to epileptic
encephalopathy with clinical features of frontal lobe epilepsy. Brain &
Development, 42, 691–695.
Jeevaratnam, K., Chadda, K. R., Huang, C. L.-H., & Camm, A. J. (2018). Car-
diac potassium channels: Physiological insights for targeted therapy.
Journal of Cardiovascular Pharmacology and Therapeutics, 23, 119–129.
Kaczmarek, L. K. (2013). Slack, Slick and sodium-activated potassium chan-
nels. ISRN Neuroscience, 2013, 354262. https://doi.org/10.1155/
2013/354262.
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J.,
Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P.,
Gauthier, L. D., Brand, H., Solomonson, M., Watts, N. A., Rhodes, D.,
Singer-Berk, M., England, E. M., Seaby, E. G., Kosmicki, J. A., …
MacArthur, D. G. (2020). The mutational constraint spectrum quanti-
fied from variation in 141,456 humans. Nature, 581, 434–443.
Kessi, M., Chen, B., Peng, J., Tang, Y., Olatoutou, E., He, F., Yang, L., &
Yin, F. (2020). Intellectual disability and potassium Channelopathies: A
systematic review. Frontiers in Genetics, 11, 614.
Kondratskyi, A., Kondratska, K., Skryma, R., & Prevarskaya, N. (2015). Ion
channels in the regulation of apoptosis. Biochimica et Biophysica Acta,
1848, 2532–2546.
Mao, X., Bruneau, N., Gao, Q., Becq, H., Jia, Z., Xi, H., Shu, L., Wang, H.,
Szepetowski, P., & Aniksztejn, L. (2020). The epilepsy of infancy with
migrating focal seizures: Identification of de novo mutations of the
KCNT2 Gene that exert inhibitory effects on the corresponding Het-
eromeric KNa1.1/KNa1.2 Potassium Channel. Frontiers in Cellular Neu-
roscience, 14, 1. https://doi.org/10.3389/fncel.2020.00001.
Martin, H. C., Kim, G. E., Pagnamenta, A. T., Murakami, Y., Carvill, G. L.,
Meyer, E., Copley, R. R., Rimmer, A., Barcia, G., Fleming, M. R.,
Kronengold, J., Brown, M. R., Hudspith, K. A., Broxholme, J.,
Kanapin, A., Cazier, J.-B., Kinoshita, T., Nabbout, R., The WGS500
Consortium, … Taylor, J. C. (2014). Clinical whole-genome sequencing
8 JACKSON ET AL.
in severe early-onset epilepsy reveals new genes and improves molec-
ular diagnosis. Human Molecular Genetics, 23, 3200–3211.
Ohko, K., Nakajima, K., Nakajima, H., Hiraki, Y., Kubota, K., Fukao, T.,
Miyatake, S., Matsumoto, N., & Sano, S. (2020). Skin and hair abnor-
malities of Cantu syndrome: A congenital hypertrichosis due to a
genetic alteration mimicking the pharmacological effect of minoxidil.
The Journal of Dermatology, 47, 306–310.
Pontén, F., Jirström, K., & Uhlen, M. (2008). The human protein atlas—a
tool for pathology. The Journal of Pathology, 216, 387–393.
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J.,
Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., &
Rehm, H. L. (2015). Standards and guidelines for the interpretation of
sequence variants: A joint consensus recommendation of the Ameri-
can College of Medical Genetics and Genomics and the Association
for Molecular Pathology. Genetics in Medicine, 17, 405–424.
Samuelov, L., Kinori, M., Bertolini, M., & Paus, R. (2012). Neural controls of
human hair growth: Calcitonin gene-related peptide (CGRP) induces
catagen. Journal of Dermatological Science, 67, 153–155.
Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R.,
McWilliam, H., Remmert, M., Söding, J., Thompson, J. D., &
Higgins, D. G. (2011). Fast, scalable generation of high-quality protein
multiple sequence alignments using Clustal omega. Molecular Systems
Biology, 7, 539.
Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil
and its use in hair disorders: A review. Drug Design, Development and
Therapy, 13, 2777–2786.
Szabò, I., Zoratti, M., & Gulbins, E. (2010). Contribution of voltage-gated
potassium channels to the regulation of apoptosis. FEBS Letters, 584,
2049–2056.
Tomasello, D. L., Gancarz-Kausch, A. M., Dietz, D. M., & Bhattacharjee, A.
(2015). Transcriptional regulation of the sodium-activated Potassium
Channel SLICK (KCNT2) promoter by nuclear factor-κB. The Journal of
Biological Chemistry, 290, 18575–18583.
Tomasello, D. L., Hurley, E., Wrabetz, L., & Bhattacharjee, A. (2017). Slick
(Kcnt2) sodium-activated potassium channels limit Peptidergic
nociceptor excitability and hyperalgesia. Journal of Experimental Neuro-
science, 11, 1179069517726996.
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G.,
Benfeitas, R., Arif, M., Liu, Z., Edfors, F., Sanli, K., von Feilitzen, K.,
Oksvold, P., Lundberg, E., Hober, S., Nilsson, P., Mattsson, J.,
Schwenk, J. M., Brunnström, H., … Ponten, F. (2017). A pathology atlas
of the human cancer transcriptome. Science, 357, eaan2507.
Uno, H., Kemnitz, J. W., Cappas, A., Adachi, K., Sakuma, A., & Kamoda, H.
(1990). The effects of topical diazoxide on hair follicular growth and
physiology of the stumptailed macaque. Journal of Dermatological Sci-
ence, 1, 183–194.
Vaz, F. M., McDermott, J. H., Alders, M., Wortmann, S. B., Kölker, S., Pras-
Raves, M. L., Vervaart, M. A. T., van Lenthe, H., Luyf, A. C. M.,
Elfrink, H. L., Metcalfe, K., Cuvertino, S., Clayton, P. E., Yarwood, R.,
Lowe, M. P., Lovell, S., Rogers, R. C., Deciphering Developmental Dis-
orders Study, Van Kampen, A. H. C., … Banka, S. (2019). Mutations in
PCYT2 disrupt etherlipid biosynthesis and cause a complex hereditary
spastic paraplegia. Brain: A Journal of Neurology, 142, 3382–3397.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Jackson, A., Banka, S., Stewart, H.,
Genomics England Research Consortium, Robinson, H., Lovell,
S., & Clayton-Smith, J. (2021). Recurrent KCNT2 missense
variants affecting p.Arg190 result in a recognizable phenotype.
American Journal of Medical Genetics Part A Part A, 1–9.
https://doi.org/10.1002/ajmg.a.62370
JACKSON ET AL. 9
